Coronavirus: Moderna Therapeutics vaccine soon to be in its last clinical trial phase

Published by Laurent P. · Published on 15 July 2020 at 11h40 · Updated on 15 July 2020 at 11h51
The fight against coronavirus is speeding up! American laboratory Moderna has announced this Tuesday July 14 that clinical trials for the creation of avaccine will enter the third and last phase on July 27, 2020. A statement that follows the one back to mid-may on the first phase of the same trial and its “positive interim data”.

The United-States really are on their way for a vaccine against coronavirus. American laboratory Moderna announced this Tuesday July 14, 2020 that the candidate vaccine against Covid-19 will soon enter the last phase of its clinical trial on July 27. A statement taking Moderna Therapeutics to first rank of the world race for the creation of a vaccine.

This third and last phase will include 30,000 people in the United States. As for the trial protocol, 15,000 of them will be given a 100 microgram dose of the vaccine, the other 15,000 will be given a placebo. The clinical trial is said to last two years and will determine if there really is protection against coronavirus, and if, in case of an infection, the vaccine can "prevent the progression of symptoms" by preventing the worsening of cases and the death risk. Note the first results will be released far earlier.

Back to mid-May, Moderna already gave news of their clinical trials and shared “positive interim data” as for the first phase of a clinical trial for a vaccine project against Covid-19. What does it mean? It means that after injecting the currently studied vaccine, called mRNA-1273, some patients’ bodies elicited an encouraging immune response “of the magnitude caused by natural infection” according to our peers from Challenges, quoting the laboratory’s released.

These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection” Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna. What is this clinical trial about? Carried out by NIH, it includes 45 patients divided into three groups of 15, each given three different doses of vaccines, in one or two shots. All in all, 40 volunteers of the clinical trial elicited this immune response and eight of them developed neutralizing antibodies. A first phase which official results are yet expected in order to move on to the next step and produce a vaccine at the end.

The Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July” Chief Executive Officer at Moderna Stéphane Bancel explains. The last phase, that many searchers and leaders will thoroughly browse, to know if this is an effective vaccine or not.

Practical information

Comments
Refine your search
Refine your search
Refine your search
Refine your search